Masayuki Okamoto, M. Fujiwara, Eiichi Kodama
Mar 1, 1999
Citations
0
Influential Citations
9
Citations
Quality indicators
Journal
Antiviral Chemistry and Chemotherapy
Abstract
We have examined novel benzylhydroxylamine derivatives for their inhibitory effects on the replication of human immunodeficiency virus (HIV) in cell cultures. Among the series, O-(2-chloro-6-fluo-robenzyl)hydroxylamine (RD6-Y664) was found to be the most potent inhibitor of HIV-1. The EC50 for HIV-1 strain IIIB was 1.6 μg/ml with a selectivity index greater than 38 in MT-4 cells. It also inhibited the replication of other HIV strains including a nonnucleoside reverse transcriptase (RT) inhibitor-resistant mutant, a nucleoside RT inhibitor-resistant mutant and HIV-2, in acutely infected cells. However, the compound did not affect HIV-1 production in chronically infected cells. A time-of-addition experiment and detection of proviral DNA synthesis suggested that RD6-Y664 targeted an early step of the viral replication cycle, presumably a process prior to reverse transcription. In fact, an assay for HIV-1 RT revealed that the compound did not suppress enzyme activity. Furthermore, RD6-Y664 did not show any inhibition of gp120–CD4 interaction, or binding of anti-CXCR4 antibody to CXCR4.